1. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report.
- Author
-
Lee, Thomas, Aisner, Dara, David, Marjorie, Eno, Celeste, Gagan, Jeffrey, Gocke, Christopher, Guseva, Natalya, Haley, Lisa, Jajosky, Audrey, Jones, Daniel, Mansukhani, Mahesh, Mroz, Pawel, Murray, Sarah, Newsom, Kimberly, Paulson, Vera, Roy, Somak, Rushton, Chase, Segal, Jeremy, Senaratne, T, Siddon, Alexa, Starostik, Petr, Van Ziffle, Jessica, Wu, David, Xian, Rena, Yohe, Sophia, and Kim, Annette
- Subjects
Humans ,Goals ,Hematologic Neoplasms ,Genomics ,High-Throughput Nucleotide Sequencing - Abstract
While molecular testing of hematologic malignancies is now standard of care, there is variability in practice and testing capabilities between different academic laboratories, with common questions arising on how to best meet clinical expectations. A survey was sent to hematopathology subgroup members of the Genomics Organization for Academic Laboratories consortium to assess current and future practice and potentially establish a reference for peer institutions. Responses were received from 18 academic tertiary-care laboratories regarding next-generation sequencing (NGS) panel design, sequencing protocols and metrics, assay characteristics, laboratory operations, case reimbursement, and development plans. Differences in NGS panel size, use, and gene content were reported. Gene content for myeloid processes was reported to be generally excellent, while genes for lymphoid processes were less well covered. The turnaround time (TAT) for acute cases, including acute myeloid leukemia, was reported to range from 2 to 7 calendar days to 15 to 21 calendar days, with different approaches to achieving rapid TAT described. To help guide NGS panel design and standardize gene content, consensus gene lists based on current and future NGS panels in development were generated. Most survey respondents expected molecular testing at academic laboratories to continue to be viable in the future, with rapid TAT for acute cases likely to remain an important factor. Molecular testing reimbursement was reported to be a major concern. The results of this survey and subsequent discussions improve the shared understanding of differences in testing practices for hematologic malignancies between institutions and will help provide a more consistent level of patient care.
- Published
- 2023